Journal of Neural Transmission

, Volume 126, Issue 1, pp 27–33 | Cite as

Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain

  • Malgorzata Maciukiewicz
  • Ilona Gorbovskaya
  • Arun K. Tiwari
  • Clement C. Zai
  • Natalie Freeman
  • Herbert Y. Meltzer
  • James L. Kennedy
  • Daniel J. MüllerEmail author
Translational Neurosciences - Original Article


Schizophrenia is a severe, debilitating disorder with a lifetime prevalence of 1% irrespective of gender or ethnicity and is typically treated with antipsychotic drugs. Antipsychotic-induced weight gain (AIWG) is a leading factor of patient non-compliance and has previously been shown to increase the risk of type 2 diabetes, metabolic syndrome, and cardiovascular events. The current study intends to replicate findings from a recent genome-wide association study in Han-Chinese patients implicating two gene variants (rs10977144 and rs10977154) of the protein tyrosine phosphatase receptor type D (PTPRD) in antipsychotic-induced weight gain (AIWG). We investigated a sample of European and African American ancestry (n = 201) and calculated percentage of weight change using linear regression corrected for type of antipsychotics, duration of treatment and principal components from ancestry checks. As secondary goal, we investigated additional gene variants of PTPRD previously not associated with AIWG. We found no association with rs10977144 and rs10977154. However, we found nominally significant results between PTPRD and AIWG with rs73398242 in Europeans (BETA = − 0.267, p = 0.002) and rs13294608 in African Americans (BETA = 0.423, p = 0.003). According to Haploreg, both SNPs are histone marks for enhancers and promoters across various brain regions including the cingulate gyrus and dorsolateral prefrontal cortex. In summary, our results tentatively suggest that PTPRD might be associated with AIWG although different SNPS might be involved in different ethnic groups.


Antipsychotic-induced weight gain (AIWG) PTPRD Pharmacogenetics Antipsychotics 



This investigation received approval from the Centre of Addiction and Mental Health Research Ethics Board. We are indebted to all patients participating in our research. All included participants gave informed consent to participate.


  1. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D et al (2010) A map of human genome variation from population-scale sequencing. Nature 467:1061–1073CrossRefGoogle Scholar
  2. Anderson CA, Pettersson FH, Clarke GM et al (2010) Data quality control in genetic case-control association studies. Nat Protoc 5:1564–1573CrossRefGoogle Scholar
  3. Belfort-DeAguiar R, Seo D, Lacadie C et al (2018) Obese humans have disordered brain responses to food images during physiological hyperglycemia. Am J Physiol Endocrinol Metab. Google Scholar
  4. Below JE, Gamazon ER, Morrison JV et al (2011) Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia 54:2047–2055CrossRefGoogle Scholar
  5. Chang Y-C, Chiu Y-F, Liu P-H et al (2012) Replication of genome-wide association signals of type 2 diabetes in Han Chinese in a prospective cohort. Clin Endocrinol 76:365–372CrossRefGoogle Scholar
  6. Cheke LG, Bonnici HM, Clayton NS, Simons JS (2017) Obesity and insulin resistance are associated with reduced activity in core memory regions of the brain. Neuropsychologia 96:137–149CrossRefGoogle Scholar
  7. Clarke GM, Anderson CA, Pettersson FH et al (2011) Basic statistical analysis in genetic case-control studies. Nat Protoc 6:121–133CrossRefGoogle Scholar
  8. Czerwensky F, Leucht S, Steimer W (2013) MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 16:2103–2109CrossRefGoogle Scholar
  9. Delaneau O, Marchini J, Zagury J-F (2011) A linear complexity phasing method for thousands of genomes. Nat Methods 9:179–181CrossRefGoogle Scholar
  10. Gonçalves VF, Zai CC, Tiwari AK et al (2014) A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 39:1347–1354CrossRefGoogle Scholar
  11. Ikeda M, Tanaka S, Saito T et al (2018) Re-evaluating classical body type theories: genetic correlation between psychiatric disorders and body mass index. Psychol Med 48:1745–1748CrossRefGoogle Scholar
  12. Imamura M, Iwata M, Maegawa H et al (2013) Replication study for the association of rs391300 in SRR and rs17584499 in PTPRD with susceptibility to type 2 diabetes in a Japanese population. J Diabetes Investig 4:168–173CrossRefGoogle Scholar
  13. Kang SH, Lee J-I, Han HR et al (2014) Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia. Psychiatr Genet 24:249–256CrossRefGoogle Scholar
  14. Kim S-H, Chung J-H, Kim T-H et al (2017) The effects of repetitive transcranial magnetic stimulation on eating behaviors and body weight in obesity: a randomized controlled study. Brain Stimul. Google Scholar
  15. Kircher M, Witten DM, Jain P et al (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46:310–315CrossRefGoogle Scholar
  16. Lett TAP, Wallace TJM, Chowdhury NI et al (2012) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17:242–266CrossRefGoogle Scholar
  17. Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223CrossRefGoogle Scholar
  18. Liu L, Chen L, Li Z et al (2014) Association between gene polymorphisms of seven newly identified loci and type 2 diabetes and the correlate quantitative traits in Chinese Dong populations. Iran J Public Health 43:1345–1355Google Scholar
  19. Machiela MJ, Chanock SJ (2015) LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31:3555–3557CrossRefGoogle Scholar
  20. MacNeil RR, Müller DJ (2016) Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry 2:61–78CrossRefGoogle Scholar
  21. Malhotra AK, Correll CU, Chowdhury NI et al (2012) Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug—induced weight gain. Arch Gen Psychiatry 69:904–912CrossRefGoogle Scholar
  22. Marchini J, Howie B (2010) Genotype imputation for genome-wide association studies. Nat Rev Genet 11:499–511CrossRefGoogle Scholar
  23. Nurmi EL, Spilman SL, Whelan F et al (2013) Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry 3:e274CrossRefGoogle Scholar
  24. Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74:765–769CrossRefGoogle Scholar
  25. Opgen-Rhein C, Brandl EJ, Müller DJ et al (2010) Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 11:773–780CrossRefGoogle Scholar
  26. Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia. Lancet 388:86–97CrossRefGoogle Scholar
  27. Price AL, Patterson NJ, Plenge RM et al (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909CrossRefGoogle Scholar
  28. Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575CrossRefGoogle Scholar
  29. Tiwari AK, Brandl EJ, Weber C et al (2013) Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J Clin Psychopharmacol 33:11–17CrossRefGoogle Scholar
  30. Tiwari AK, Brandl EJ, Zai CC et al (2016) Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. World J Biol Psychiatry 17:221–229CrossRefGoogle Scholar
  31. Tsai F-J, Yang C-F, Chen C-C et al (2010) A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet 6:e1000847CrossRefGoogle Scholar
  32. Wallace TJ, Zai CC, Brandl EJ, Müller DJ (2011) Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmacogenom Pers Med 4:83–93Google Scholar
  33. Ward LD, Kellis M (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40:D930–D934CrossRefGoogle Scholar
  34. Ward J, Strawbridge RJ, Bailey MES et al (2017) Genome-wide analysis in UK Biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia. Transl Psychiatry 7:1264CrossRefGoogle Scholar
  35. Winter SR, Yokum S, Stice E et al (2017) Elevated reward response to receipt of palatable food predicts future weight variability in healthy-weight adolescents. Am J Clin Nutr 105:781–789CrossRefGoogle Scholar
  36. Yu H, Wang L, Lv L et al (2016) Genome-Wide Association Study suggested the PTPRD polymorphisms were associated with weight gain effects of atypical antipsychotic medications. Schizophr Bull 42:814–823CrossRefGoogle Scholar
  37. Zhang J-P, Lencz T, Zhang RX et al (2016) Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull 42:1418–1437CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Malgorzata Maciukiewicz
    • 1
  • Ilona Gorbovskaya
    • 1
  • Arun K. Tiwari
    • 1
    • 2
  • Clement C. Zai
    • 1
    • 2
  • Natalie Freeman
    • 1
  • Herbert Y. Meltzer
    • 4
  • James L. Kennedy
    • 1
    • 3
  • Daniel J. Müller
    • 1
    • 2
    • 3
    Email author
  1. 1.Pharmacogenetics Research ClinicCampbell Family Mental Health Research Institute, Centre for Addiction and Mental HealthTorontoCanada
  2. 2.Department of PsychiatryUniversity of TorontoTorontoCanada
  3. 3.Institute of Medical Science, Faculty of MedicineUniversity of TorontoTorontoCanada
  4. 4.Department of Psychiatry and Behavioral SciencesNorthwestern UniversityChicagoUSA

Personalised recommendations